Skip to main content

Advertisement

SpringerLink
Log in

Positron Emission Tomography (PET) has Limited Utility in the Staging of Pancreatic Adenocarcinoma

  • Original Article
  • Published:
Journal of Gastrointestinal Surgery

Abstract

Background

Positron emission tomography (PET) as an adjunct to conventional imaging in the staging of pancreatic adenocarcinoma is controversial. Herein, we assess the utility of PET in identifying metastatic disease and evaluate the prognostic potential of standard uptake value (SUV).

Methods

Imaging and follow-up data for patients diagnosed with pancreatic adenocarcinoma were reviewed retrospectively. Resectability was assessed based on established criteria, and sensitivity, specificity, and accuracy of PET were compared to those of conventional imaging modalities.

Results

For 123 patients evaluated 2005–2011, PET and CT/MRI were concordant in 108 (88 %) cases; however, PET identified occult metastatic lesions in seven (5.6 %). False-positive PETs delayed surgery for three (8.3 %) patients. In a cohort free of metastatic disease in 78.9 % of cases, the sensitivity and specificity of PET for metastases were 89.3 and 85.1 %, respectively, compared with 62.5 and 93.5 % for CT and 61.5 and 100.0 % for MRI. Positive predictive value and negative predictive value of PET were 64.1 and 96.4 %, respectively, compared with 75.0 and 88.9 % for CT and 100.0 and 91.9 % for MRI. Average difference in maximum SUV of resectable and unresectable lesions was not statistically significant (5.65 vs. 6.5, p = 0.224) nor was maximum SUV a statistically significant predictor of survival (p = 0.18).

Conclusion

PET is more sensitive in identifying metastatic lesions than CT or MRI; however, it has a lower specificity, lower positive predictive value, and in some cases, can delay definitive surgical management. Therefore, PET has limited utility as an adjunctive modality in staging of pancreatic adenocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel, R., et al. (2011). “Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.” CA Cancer J Clin 2011 61(4): 212–236.

  2. O’Malley ME, et al. (1999) “Adenocarcinoma of the head of the pancreas: Determination of surgical unresectability with thin-section pancreatic-phase helical CT.” AJR 1999; 173: 1513–1518.

  3. McCarthy MJ, et al. (1998) “Prediction of resectability of pancreatic malignancy by computed tomography.” Br J Surg 1998; 85: 320–325.

    Article  CAS  PubMed  Google Scholar 

  4. Miura F, et al. (2006) “Diagnosis of pancreatic cancer” HPB, 2006; 8: 337_342

  5. Vellet AD, et al. (1992) “Adenocarcinoma of the pancreatic ducts: comparative evaluation with CT and MR imaging at 1.5 T.” Radiology 1992;/183:/87_95.

  6. Stollfuss JC, et al. (1995) “2-(fluorine-18)-fluoro-2-deoxy- D -glucose PET in detection of pancreatic cancer: Value of quantitative image interpretation.” Radiology 1995; 195: 339–344.

  7. Tempero, A et al. (2012) “Pancreatic Adenocarcinoma, Version 2.2012: Featured Update to NCCN Guidelines” J Natl Compr Canc Netw 2012;10:703-713

  8. Seo, S., et al. (2008). “Contribution of 18F-fluorodeoxyglucose positron emission tomography to the diagnosis of early pancreatic carcinoma.” J Hepatobiliary Pancreat Surg 15(6): 634–639.

    Article  PubMed  Google Scholar 

  9. Imdahl, A., et al. (1999). “Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.” Br J Surg 86(2): 194–199.

    Article  CAS  PubMed  Google Scholar 

  10. Kidd, E. A., et al. (2007). “The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival.” Cancer 110(8): 1738–1744.

    Article  PubMed  Google Scholar 

  11. Imsande, H. M., et al. (2011). “Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma.” AJR Am J Roentgenol 197(4): 976–980.

    Article  PubMed  Google Scholar 

  12. Lyshchik A, et al. “Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer.” Eur J Nucl Med Mol Imaging 2005;32:389–397.

    Article  PubMed  Google Scholar 

  13. Wakabayashi H, et al. (2008) Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer.” World J Gastroenterol 2008;14:64–69

Download references

Disclosures

This work was selected as a Poster of Distinction at the 54th Annual Meeting of the Society for Surgery of the Alimentary Tract (SSAT) and as a Long Oral Presentation at the 47th Annual Meeting of the Pancreas Club both held in May 2013.

Author information

Authors and Affiliations

  1. CUMC Department of Radiology, Columbia University, New York, NY, USA

    David Leung

  2. CUMC Department of Surgery, Columbia University, 161 Fort Washington Avenue, Suite 820, New York, NY, 10032-3784, USA

    John A. Chabot & John D. Allendorf

  3. Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, NY, USA

    Peter Einersen, Irene Epelboym & Megan D. Winner

  4. Winthrop University Medical Center, New York, NY, USA

    John D. Allendorf

Authors
  1. Peter Einersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Irene Epelboym
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Megan D. Winner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John A. Chabot
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John D. Allendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John D. Allendorf.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Einersen, P., Epelboym, I., Winner, M.D. et al. Positron Emission Tomography (PET) has Limited Utility in the Staging of Pancreatic Adenocarcinoma. J Gastrointest Surg 18, 1441–1444 (2014). https://doi.org/10.1007/s11605-014-2529-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-014-2529-x

Keywords

Search

Navigation